# Recurrent Aggressive Hepatocellular Carcinoma Presenting With Chest Wall Metastasis and Portal Vein Thrombosis: A Rare Case and a Multidisciplinary Perspective

**Authors:** Nasim Salimiaghdam, Ahmed Mustafa, Irene O Pokuaa, Afshin Hamidi, Emily Chen

PMC · DOI: 10.7759/cureus.87330 · Cureus · 2025-07-05

## TL;DR

A rare case of aggressive liver cancer spreading to the chest wall and causing blood clot is reported, emphasizing the need for multidisciplinary care.

## Contribution

Presents a rare metastatic pattern of hepatocellular carcinoma involving the chest wall and portal vein thrombosis.

## Key findings

- Metastatic HCC was confirmed with chest wall mass and portal vein thrombosis in a patient with prior HCC resection.
- Immunohistochemical staining showed HepPar-1 and glypican-3 positivity, confirming HCC metastasis.
- The case underscores the importance of multidisciplinary management for atypical HCC presentations.

## Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, often presenting with aggressive intrahepatic and extrahepatic spread. Extrahepatic metastasis occurs in a significant proportion of advanced HCC cases, most commonly affecting the lungs, regional lymph nodes, bones, and adrenal glands. However, metastasis to the chest wall is exceedingly rare and infrequently reported in the literature.

We report an unusual case of a 71-year-old male with chronic hepatitis C infection and a history of HCC resection in 2019, who presented with abdominal distension, lower extremity edema, and a rapidly enlarging chest wall mass. Imaging and biopsy confirmed metastatic HCC, showing trabecular architecture and positive immunohistochemical staining for HepPar-1 and glypican-3, with portal vein thrombosis (PVT) and chest wall involvement - a rare metastatic pattern. This case highlights HCC’s aggressive nature, the importance of early recognition of atypical metastases, and the value of multidisciplinary management - encompassing oncology, hepatology, radiology, and pathology - in improving patient outcomes.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}
- **Diseases:** pleural effusion (MESH:D010996), hypertension (MESH:D006973), NASH (MESH:D065626), variceal bleeding (MESH:D014648), liver dysfunction (MESH:D017093), atelectasis (MESH:D001261), solid (MESH:D018250), shortness of breath (MESH:D004417), portal hypertension (MESH:D006975), diarrhea (MESH:D003967), inflammation (MESH:D007249), chronic infections (MESH:D000088562), Tumor thrombi (MESH:D009369), ascites (MESH:D001201), atrophy (MESH:D001284), Metastasis (MESH:D009362), soft tissue sarcoma (MESH:D012509), cirrhosis (MESH:D005355), chronic liver disease (MESH:D008107), hepatic lesions (MESH:D056486), ventral hernia (MESH:D006555), cholestasis (MESH:D002779), cirrhotic (MESH:D000094724), fever (MESH:D005334), abscess (MESH:D000038), wall (MESH:D056988), MASH (MESH:D005234), PVT (MESH:D012170), localized pain (MESH:D010146), melena (MESH:D008551), alcoholic liver disease (MESH:D008108), chest (MESH:D013898), HCV infection (MESH:D006526), hepatic venous outflow obstruction (MESH:D006502), abdominal distension (MESH:D000007), Thrombosis (MESH:D013927), splenomegaly (MESH:D013163), chronic hepatitis C (MESH:D019698), hematemesis (MESH:D006396), lower extremity edema (MESH:D004487), bleeding (MESH:D006470), hepatitis B and C (MESH:D006509), BCLC (MESH:D006528)
- **Chemicals:** IMbrave150 (-), bevacizumab (MESH:D000068258), cabozantinib (MESH:C558660), lenvatinib (MESH:C531958), bilirubin (MESH:D001663), alcohol (MESH:D000438), sorafenib (MESH:D000077157), atezolizumab (MESH:C000594389)
- **Species:** Hepatitis C Virus [taxon 11103], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12320916/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12320916/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12320916/full.md

---
Source: https://tomesphere.com/paper/PMC12320916